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Abstract: The purpose of this study was the investigation of the targeting potential of 99mTc-Labeled 
dendrimer-phenylalanine conjugate for brain tumor SPECT imaging. L-Type amino acid transporters 
(LAT1) are highly expressed in the blood-brain barrier as well as in brain cancer cells; thus, targeting 
LAT1 using phenylalanine could improve the sensitivity and specificity of radiosynthesis nanocarrier. 
In this study, the dendrimer G2–phenylalanine conjugate was synthesized and characterized by Fourier 
transform infrared spectroscopy, atomic force microscopy, particle size, and zeta potential. MTT assay 
was done for cell viability measurement in different concentrations of nanoparticles (0.125, 0.25, 0.5 
mg/ml) on C6 glioma cell lines; the uptake study was evaluated using fluorescence-activated cell sorter 
(FACS) instrument; finally, SPECT scintigraphy in glioma tumor-bearing Wistar rats was done. The 
dendrimer-phenylalanine conjugate particle size was found in the range of 74.14±2.2 to 109±3.1 nm, 
with a slightly negative surface charge. Also, phenylalanine present on the dendrimer's surface–
phenylalanine conjugate enhanced the dendrimer's cellular uptake–phenylalanine conjugate on the C6 
glioma cell line. Results of SPECT imaging and fluorescence studies revealed that dendrimer–
phenylalanine conjugate accumulated into the brain tumor cells, and it can be suggested as a promising 
brain-targeting probe with no toxicity in brain tumor imaging.  
Keywords: dendrimer G2; LAT1; phenylalanine; glioma; carrier-mediated transport; SPECT. 
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1. Introduction 
Malignant glioma such as glioblastoma multiform (GBM) is one of the most significant 
challenges in front of cancerous patients worldwide. World Health Organization (WHO) has 
categorized  gliomas based on histological characteristics as grades I-IV. A WHO grade IV 
glioma is glioblastoma. Glioblastoma (GBM) is the most malignant grade and most common 
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primary brain tumor [1-5]. The average patient’s survival is about 1.5 years despite typical 
treatments, including surgery, chemotherapy with alkylating agents such as temozolomide, and 
ionizing radiation. However, early detection of cancer greatly increases the chance of 
successful treatment and survival. To diagnose cancer at the earliest stage, novel, and more 
effective targeted therapeutic and diagnostic agent delivery systems are needed [6,7]. Most 
therapeutic and contrast agents do not readily permeate the blood-brain barrier (BBB) [8,9]. 
BBB trafficking is the main limiting factor for delivering potential CNS drugs into the brain 
parenchyma, which makes it the interest of CNS drug designing. BBB is configured from 
capillary endothelial cells with tight intercellular junctions and surrounded by a basement 
membrane, astrocytes, and pericytes. BBB has a high electrical resistivity, 1500-2000(1300) 
Ωcm2 (compared with other organs having an average resistance of 1.8 Ωcm2). Tight junctions 
and basal membranes are responsible for the integrity and maintenance of the barrier [10-
12](Figure 1). Some parameters should be considered for designing ideal carriers, including 
tight junction, electrical resistance, efflux proteins, and catalyzing enzymes [13,14]. For 
passive diffusion from BBB, hydrophobic, and hydrophilic agents' molecular weight must be 
less than 400-600 KDa with less than 8-10 hydrogen bands [15-18]. In addition, since diffusion 
depends on concentration, high concentration in capillary promotes diffusion. Due to these 
restrictions, 98% of small molecules and 100% of large molecules like antibodies, even 
engineering antibodies (around 15-150 KDa) do not pass BBB. These mentioned mechanisms 
are responsible for 98% of drugs that can not pass BBB [19-21]. It could be concluded that 
small lipophilic molecules with less protein binding (PB) and long serum half-life are good 
candidates to cross BBB. With this regard, lipophilicity, size, and ionization degree should be 
considered in designing BBB trafficable agents [22]. Carrier is conjugated to amino acids, 
glucose, nucleosides, or bigger molecules like insulin and transferrin to pass BBB [23,24]. 
Therapeutic or contrast agent delivery based on tumor cells' metabolism has shown significant 
success in recent years [25-33]. Amino acids are essential for cell growth and proliferation 
[34]. The L-type amino acid transporter-1 (LAT-1) can transport large, branched-chain and 
aromatic, neutral amino acids. Previous studies have shown a relationship between LAT1 level 
and tumor growth [35,36]. LAT1 expression is increased in several cancers [37-44]. Several 
studies have recently demonstrated the effectiveness of LAT-1 targeting for drug and contrast 
agent delivery in a wide range of cancers like breast cancer and glioma [25-33,45-53]. 
Recent studies have shown that the expression of LAT1 increases in glioma. 
Phenylalanine is an essential amino acid required for protein synthesis and is one of the LAT1 
substrates. Therefore, targeting glioma cancer cells with the Phenylalanine ligand is suitable 
for targeting cancer cells [33,54-56]. 
Today, nanoparticles in disease diagnosis and therapy are an interesting field for 
researchers [27,57-71]. Nanoparticles can enhance drug dissolution; because of their small size, 
they can cross the membrane barrier. Another advantage is the possibility of particles targeted 
in a particular organ. Dendrimers are a family of compact spherical polymers at the nanoscale. 
They have numerous and diverse applications, including the biomedical field (i.e., drug 
delivery, cancer diagnostics). In this study, anionic G2 dendrimer (polyethylene glycol-citric 
acid) was synthesized using a simple method without the use of toxic and harmful agents. 
Several modalities such as SPECT, PET, CT, and MRI have been introduced in 
metabolic imaging [72-76]. The purpose of this study was the investigation of 99m Tc-labeled 
dendrimer–phenylalanine conjugate potential for brain tumor SPECT imaging. L-Type amino 
acid transporters (LAT1) are highly expressed on the blood-brain barrier as well as on many 
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brain cancer cells, thus targeting LAT1 using phenylalanine improved sensitivity and 
specificity of radiosynthesis nanocarrier 
In the present research work, an L-type amino acid transport system was utilized to 
cross BBB. The phenylalanine was used as a targeting ligand, which was conjugated on the 
dendrimer's surface labeled with 99mTc as shown in Figure 2.        
 
Figure 1. Schematic structure of BBB. 
 
Figure 2. Schematic illustrates the transportation of  Dendrimer-Phenylalanin across BBB and uptake by the 
brain tumor cell.      
2. Materials and Methods 
 2.1. Chemical materials. 
Phenylalanine (PA), Sephadex G-50, and 1-ethyl-3-(3-dimethyl aminopropyl) 
carbodiimide hydrochloride (EDC), sulfo-N-hydrosuccinimide (sulfo-NHS), triethylamine, 
dimethylformamide, MTT, and stannous chloride dihydrate were purchased from Sigma 
Chemicals (St Louis, MO, USA). Polyethylene glycol, citric acid anhydrous, sodium 
bicarbonate, methanol were purchased from Merck, Solvents, and chemical reagents were 
analytical grade from Merck. 
2.2. Cell culture. 
C6 cell line was supplied by the Pasteur Institute of Iran and used for cell cytotoxicity 
and imaging studies. The cells were cultured in complete RPMI-1640 medium, supplemented 
with 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C with 5% CO2. 
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2.3. Animal models. 
All animal experiments were done according to the guideline of the INMAS animal 
ethics committee. Miura et al. and Shahmabadi et al. protocols were used for tumor formation, 
50.000 cells of C6 cells in 10 μl of PBS were injected into the frontal lobe of the skull of a male 
rat (200-250g, n=5) [9,77]. 
2.4. Preparation of dendrimer G2-phenylalanine conjugate dendrimer (G2) synthesis. 
Dendrimer was synthesized using the method reported previously [26-28,59,61,62]. 
Briefly, polyethylene glycol (PEG) with two carboxyl groups on the sides formed the core, and 
citric acid formed the dendrimer's shell. PEG600, engineered Polyethylene glycol, (5.65 
mmoles) was added to dried Dimethyl Sulfoxide (DMSO), and Cacl2 then mixed for 10 
minutes. N, N’- Dicyclohexylcarbodiimide (DCC) (2mM) was added and mixed for 15 
minutes. 0.5gr citric acid was added to the reaction container and stirred at 400 rpm for 1h. In 
the next step, to synthesize the second generation, DCC (3 mM) was added. Then citric acid 
(5.2mM) was added to the reaction and stirred at 400 rpm for 7 days. The color change to a 
dark brown color verified the synthesis of the G2 dendrimer. Filter paper, chromatography 
against Cephadex, and lyophilization were used to purify dendrimer (G2) purification. 
2.5. Conjugation phenylalanine on the surface of dendrimer G2. 
The amine group of phenylalanine was covalently coupled to the carboxyl group of 
dendrimer (G2), phenylalanine was decorated on the surface of the dendrimer. Briefly, the 
phenylalanine's free amine functional group reacts to carboxyl groups of the G2 dendrimers via 
an amide bond. In the final step, the BODIPY (fluorescent dye) was loaded into the synthesized 
G2 dendrimer- phenylalanine (Figure 3). To remove the unentrapped Bodipy, the nanoparticle 
was dialyzed against DDW under sink conditions for 4h.  
 
Figure 3. Schematic presentation of preparation of Dendrimer G2-Phenylalanine. 
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2.6. Characterization of nanoparticles. 
Mean size, size distribution, and zeta potential of particles were determined by 
Zetasizer (Zetasizer Nano ZS; Malvern Instruments, Malvern, UK). The conjugation of 
phenylalanine on the surface of Dendrimer G2 is confirmed by the FTIR analyses (NEXUS 
870; Thermo Fisher Scientific, Waltham, MA, USA). 
2.7. 99mTc radio-labeling of dendrimer -phenylalanine conjugates. 
Dendrimers (3.4 mg/ml) in a sterile water suspension were labeled with 99m Tc 
pertechnetate (99mTcO42) at pH 3.4, stannous chloride (SnCl2.2H2O) has been used as a 
reducing agent.99mTcO42 at 300–700 MBq/0.7 ml, eluted from a 99Mo/99mTc generator (DRN 
4329; Ultratechnekow FM), was injected into a sterile vacuum collection vial, following, 0.5 
mg of SnCl2.2H2O was dissolved in 0.5ml of distilled water, and the solution was stirred for a 
few seconds and passed through a 0.22-mm Millipore filter and was added into the vial 
containing the 99mTcO4- nanoparticle, gently shaken for 30 s and incubated for 60 min at RT. 
2.8. Radiochemical purity. 
99mTc-dendrimer- Phenylalanine complex was analyzed with ITLC-SG using the 
method reported previously [26]. 
2.9. In vitro cytotoxicity of dendrimer -phenylalanine. 
The in vitro cytotoxic effect of Dendrimer -Phenylalanine was examined using the 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, using C6 glioma 
cell line. The cells were seeded at a density of 2×104 cells per well in 96-well plates; then, the 
plates were incubated for 24 h in a humidified incubator with a CO2 concentration of 5% to 
permit adherence of the cells. Then, the cells were incubated either 0.1ml of medium containing 
Dendrimer -Phenylalanine at different iron concentrations (0.125, 0.25, 0.5mg/ml) for 4h. After 
the incubation time, 10μl of 5mg/ml MTT solution was added. Incubation was continued for a 
further 4h. Purple formazan crystals were (indicating cell viability) were solubilized by adding 
100μl DMSO per well. The absorbance was measured at 570nm by the Statfax-microplate 
reader (Statfax, Awareness Technology, Inc, USA). Experiments were performed in triplicate, 
and cell survival was determined as a percentage of viable cells in comparison with control 
wells. All assays were performed in triplicate for each concentration. Cell survival was 
determined as a percentage of viable cells compared to controls (cell line without ant 
treatment). 
2.10. Cellular uptake study. 
The uptake study was measured using a fluorescence-activated cell sorter (FACS) 
instrument (BD bioscience, FACSv Vantage California, USA).C6 glioma cell lines used in the 
study were cultured in the set of 12-well flat-bottom plates at a density of 3˟10 5cells/well, 
supplemented with 10% FBS and1 % antibiotic and incubated at 37ᵒC in a humidified 
atmosphere containing 5% CO2 for 24h. Adhered cells were treated with Bodipy-loaded 
Dendrimer G2-Phenylalanine (300µg/well) and incubated for 1h. Cells were washed twice with 
phosphate saline buffer (PBS, pH 7.4); the following cells were harvested by adding 1ml PBS 
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(pH 7.4) sonicated five times to lysate the cells. Finally, cell lysate was centrifuged (10,000 
rpm, 10min), the supernatant was used for fluorescence assay using FACS. 
2.11. SPECT scintigraphy in tumor-bearing Wistar rats. 
The rats were divided into two groups. The first group was treated with 99mTc-
unconjugated Dendrimer, and the second group with 99mTc -Dendrimer -phenylalanine. 1ml 
(3.7 MBq) of the labeled complex (0.1μM of each complex) was administered to each group 
through the tail vein. Rats were then placed in the planar gamma camera, and images were 
taken at 1h after injection. 
3. Results and Discussion 
3.1. Characterization of nanoparticles. 
Zeta potential and size of dendrimer and dendrimer-phenylalanine were shown in 
table1. Significant change following the Phenylalanine conjugation was found (74.14±2.2 nm 
and -5.21±1.1 mv to 104.9±3.1 nm and -9.01±1.8mv respectively). 
Table 1. Size and zeta potential distributions of the Dendrimer G2 and Dendrimer G2- Phenylalanine. 
Agent Size distribution, mean(nm) Zeta potential (mv) 
Dendrimer G2 74.14±2.2 -5.21±1.1 
Dendrimer G2- Phenylalanine 104.9±3.1 -9.1±1.8 
3.2. FT-IR result. 
FT-IR results of Dendrimer G2 and Dendrimer Phenylalanine were compared and 
showed in Figure 4. The peaks between 3200-3600cm-1 are related to NH and OH groups. The 
peak 1590-1760 wavelength shows carbonyl groups of the compound, aliphatic carbon-
hydrogen. 1738.4 cm-1 peak that exclusively depicts the dendrimer; this also is in dendrimer 
G2-Phenylalanine (Figure 4). 
  
Figure 4. FT-IR spectrum of Dendrimer G2 and Dendrimer G2-Phenylalanine, respectively. Abbreviation: 
FTIR: Fourier transform infrared spectroscopy. 
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3.3. In vitro cytotoxicity of nanoparticles. 
MTT assay was done on the C6 cell line to investigate the cytotoxic potential of 
nanoparticles. The results of the MTT assay exhibit no toxicity for Dendrimer G2-
Phenylalanine (Figure 5). 
 
Figure 5. MTT cytotoxicity assay of Dendrimer G2-Phenylalanine measurement in different concentrations of 
nanoparticle (0.125, 0.25, 0.5 mg/ml). Abbreviation: MTT : 3-(4,5-Dimethylthiazol-2-Yl)-2,5-
Diphenyltetrazolium Bromide. 
3.4. Cellular uptake using flow cytometry. 
The flow cytometric analysis was utilized to verify the potential of G2-Phenylalanine 
to target LAT1 transporter that overexpressed on glioma cells. C6 cell line was incubated with 
G2-Phenylalanine-BODIPY nanoparticles (300 µg), and cellular uptake was measured using 
fluorescence-activated cell sorter (FACS) instrument (BD bioscience, FACS vintage 
California, USA). 95.13±0.6 % and 98.02%±0.8 uptakes were observed with Dendrimer G2-
BODIPY and Dendrimer G2-Phenylalanine-BODIPY, respectively, after 1h (Figure 6). 
 
Figure 6. Flow cytometry studies for cellular uptake of Dendrimer G2-Phenylalanine-BODIPY and Dendrimer 
G2- loaded with BODIPY. Present PEG on the surface of Dendrimer promotes the uptake of nanoparticles 
(95.13±0.6 %). C6 cell line treated with G2-Phenylalanine-BODIPY exhibited strong green fluorescence 
(98.02±0.8 %). 
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3.5. SPECT scintigraphy in tumor-bearing Wistar rats. 
The planar and SPECT projections were made with Siemens Healthcare Global. The 
uptake of radioactivity in the brain of rat bearing C6 glioma cells after 1h into the tail vein 
injection of Dendrimer G2 and Dendrimer G2-Phenylalanine was visualized on the images                 
(Figure 7 and Table 2). 
 
Figure 7. SPECT/CT images of rat bearing C6 glioma cells 1h after injection with 99mTc-Dendrimer G2 AND 
99mTc-Dendrimer G2-Phenylalanine. Abbreviation: SPECT: Single Photon Emission Computed Tomography.  
Table 2 exhibits 99m Tc count in Dendrimer G2, Dendrimer G2-Phenylalanine, and Dendrimer G2-
Phenylalanine / Dendrimer G2 99m Tc count ratio in the rat bearing C6 glioma cell’s brain. 
 Dendrimer G2-Phenylalanine Dendrimer G2 Dendrimer G2-Phenylalanine / Dendrimer G2 ratio 
Max 11053 6876 1.67 
Min 5668 3544 1.59 
Ave 7279.13 4594.83 1.58 
Std. Dev 1851.29 1314.3  
4. Conclusions 
 The present study demonstrated the feasibility of labeling Dendrimer G2-Phenylalanine 
with 99mTc. Using in vitro and in vivo studies, we verified that the targeted Dendrimer G2 agent 
can deliver 99mTc through the BBB and preferentially target the glioma cells in a rat model of 
glioma. After the tail vein injection, the accumulation of 99mTcDendrimer G2-Phenylalanine 
was verified by SPECT/CT detection in the rat’s brain. Our results provide a promising avenue 
for future researches toward finding novel approaches to treat neurological diseases. 
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